Tabit, C
BPC-157 (Body Protection Compound-157) Purported Benefits: Accelerated wound healing Reduced inflammation Improved joint and gut health Potential Risks and Complications: Unknown Long-Term Effects: With limited human studies, the long-term impact on organs and systems is unknown
Lu HL, Wang ZY, Huang X, Han YF, Wu YS, Guo X, et al
Degradation assay Cells were treated in serum-free medium plus 11 mM glucose agonist (100 nM) before lysis (20 mM Tris base, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.5% Triton X-100 plus complete mini EDTA-free protease inhibitor (Roche)), addition of urea sample buffer (100 mM Tris-HCl pH 6.8, 2.5% SDS, 4 M urea, 100 mM DTT, 0.05% bromophenol blue), 10 min incubation at 37 C and immunoblotting
This is reactive hypoglycemia, and it is especially common during the first few weeks of treatment and after dose increases
This hypothesis is thought-provoking and deserves thorough investigation